Targeted Degradation of sGRP78 Alleviates the Immunosuppressive Tumor Microenvironment
Advanced Science · 2025
DOI: 10.1002/advs.202509921 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Zhenghao Wu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, School of Basic Medicine, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic In…. Hauptthemen laut MEDLINE: Tumor Microenvironment, Breast Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Hubei Provincial Department of Science and Technology Key Innovation Program, Natural Science Foundation of Hubei Province.
Abstract (Originalsprache)
There is an urgent need for appropriate methods to identify patients who are sensitive to neoadjuvant therapy (NAT) for precise stratified treatment. Based on clinical proteomics screening and further validation in patient cohorts, we reported that soluble glucose‐regulatory protein 78 (sGRP78) could be a serological biomarker to infer the poor chemotherapy response in breast cancer. Consequently, an “sGRP78 index” was established to accurately predict patient responses to NAT. When exploring the linked mechanisms on how sGRP78 confer the resistance, it was found that in high sGRP78 index tumors, there were more IL‐10+/PD‐L1+ B subsets and Tregs infiltration, accompanied by accelerated tumor progression and metastasis. The following experiment revealed that sGRP78 bound with tumor‐infiltrating B cells, converting the latter into IL‐10+/PD‐L1+ ones, thereby promoting Treg formation and suppressing T cell‐mediated antitumor cytotoxicity. By fusing the GRP78‐selective protease subtilase cytotoxin catalytic A subunit (subA) with a nanobody against HER2, we achieved the targeted degradation of sGRP78 within the breast cancer region, effectively reversing the immunosuppressive microenvironment. Our findings highlight the potential of sGRP78 index as a predictive signature to identify patients’ sensitivity to NAT, as well as the potential of sGRP78 as a novel immune checkpoint target for cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, School of Basic Medicine, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Wuha…
- Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
- Department of Nuclear Medicine, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China.
ORCID-Profile: Zhenghao Wu, Tao Huang, Ping Lei
Förderung
- National Natural Science Foundation of China
- Hubei Provincial Department of Science and Technology Key Innovation Program
- Natural Science Foundation of Hubei Province
Zitieren
APA
Wu, Z., Zheng, P., Xiao, Y., Wang, Q., Pan, X., Zhou, X., Lv, Y., Xiao, J., He, Y., Huang, T., & Lei, P. (2025). Targeted Degradation of sGRP78 Alleviates the Immunosuppressive Tumor Microenvironment. Advanced Science. https://doi.org/10.1002/advs.202509921
Vancouver
Wu Z, Zheng P, Xiao Y, Wang Q, Pan X, Zhou X, et al. Targeted Degradation of sGRP78 Alleviates the Immunosuppressive Tumor Microenvironment. Advanced Science. 2025. doi:10.1002/advs.202509921
BibTeX
@article{Wu2025,
author = {Wu, Zhenghao and Zheng, Peng and Xiao, Yunxiao and Wang, Qianheng and Pan, Xin and Zhou, Xiaoqi and Lv, Yibing and Xiao, Junyi and He, Yong and Huang, Tao and Lei, Ping},
title = {Targeted Degradation of sGRP78 Alleviates the Immunosuppressive Tumor Microenvironment},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202509921}
}
EUVIMED